Journal of Clinical Oncology - ASCO Publications
Dec 16, 2024 · Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Oct 17, 2022 · Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. 1 Almost 150,000 new cases and more than 50,000 deaths from CRC are reported each year in the United States. 2 In recent decades, the overall incidence of CRC has decreased among older adults because of screening and lifestyle factors; however, at the same time, incidence is increasing among younger adults. 3 ...
Survival in Patients With Brain Metastases: Summary Report on the ...
Sep 15, 2020 · Significant prognostic factors varied by diagnosis and new prognostic factors were identified. Those factors were incorporated into the updated GPA with robust separation (P < .01) between subgroups.Survival has improved, but varies widely by GPA for patients with non–small-cell lung, breast, melanoma, GI, and renal cancer with brain metastases from 7-47 months, 3-36 months, 5-34 months, 3 ...
Prevention and Management of Chemotherapy-Induced …
Jul 14, 2020 · The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged.Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional ...
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to …
Recent data from US centers show that low-dose tamoxifen is the most popular choice of preventive therapy in women with high-risk lesions, with low discontinuation rates at 1 year compared with the standard dose and other preventive drugs. 5,6 To confirm the durability of the effect and assess long-term safety associated with 3 years of low-dose tamoxifen, here, we report the 10-year analyses ...
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO …
There were approximately 725,000 new cases and 664,000 deaths worldwide due to hepatocellular carcinoma (HCC) in 2020. HCC comprises 75%-85% of primary liver cancer cases and is the fourth-leading cause of annual cancer deaths worldwide. 1 In the United States, it is estimated that liver cancer will account for approximately 41,210 new cases and about 29,380 deaths in 2023. 2 Risk factors vary ...
Management of Immune-Related Adverse Events in Patients …
Immunotherapy has revolutionized the treatment of many different types of cancers. Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1), and PD ligand 1 (PD-L1) work by preventing the receptors and ligands from binding to each other, thereby disrupting signaling so that T cells can recognize and attack cancer ...
Evidence-Based Management of Oral Mucositis | JCO Oncology …
Feb 3, 2020 · As well described in the clinical review by Brown and Gupta 1 in this issue of JCO Oncology Practice, oral mucositis is a common toxicity of cancer therapy.The morbidity of oral mucositis includes pain, nutritional compromise, and infection risk, which potentially result in breaks or dose reductions in cancer therapy.
Systemic Treatment of Patients With Metastatic Breast Cancer: …
Jan 10, 2024 · Clinicians should recommend treatment according to menopausal status, pathological and biomarker features when quality results are available. In first-line, for hormone receptor (HR)–positive MBC, when a non-steroidal aromatase inhibitor and CDK 4/6 inhibitor combination is unavailable, use hormonal therapy alone.
Vaccination of Adults With Cancer: ASCO Guideline
Mar 18, 2024 · ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow ...